Skip to main content
SpringerLink
Log in

Antibody and immunomodulatory agents in treatment of indolent non-Hodgkin's lymphoma

  • Published:
Current Treatment Options in Oncology Aims and scope Submit manuscript

Opinion statement

Immunomodulatory agents, including cytokines, monoclonal antibodies, and CpG oligonucleotides, have properties that suggest they have the ability to augment rituximab in the treatment of non-Hodgkin's lymphoma. Although several clinical trials have promising results, no randomized trials of reasonable size have been performed to date, limiting the ability to discern whether combinations of immunomodulatory agents with rituximab impact clinical outcome. Until such trials are mature, we do not recommend using these agents in combination outside of the research setting.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Nadler LM, Stashenko P, Hardy R, et al.: Serotherapy of a patient with a monoclonal antibody directed against a human lymphoma-associated antigen. Cancer Res 1980, 40:3147–3154.

    PubMed  CAS  Google Scholar 

  2. McLaughlin P, Grillo-Lopez AJ, Link BK, et al.: Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 1998, 16:2825–2833. This trial led to the approval of rituximab in the United States and is the basis for comparison of most studies discussed in this article.

    PubMed  CAS  Google Scholar 

  3. Ghielmini M, Schmitz SF, Cogliatti SB, et al.: Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly x 4 schedule. Blood 2004, 103:4416–4423

    Article  PubMed  CAS  Google Scholar 

  4. Ghielmini M: Multimodality therapies and optimal schedule of antibodies: rituximab in lymphoma as an example. Hematology (Am Soc Hematol Educ Program) 2005, 321–328.

  5. Gordon LI, Solal-Celigny P, Gascoyne RD, Freedman AS: Follicular lymphoma: management options in the era of targeted therapy. In ASCO Educational Book. 2005:511–526.

  6. Friedberg JW: Unique toxicities and resistance mechanisms associated with monoclonal antibody therapy. Hematology (Am Soc Hematol Educ Program) 2005, 329–334.

  7. Smith MR: Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance. Oncogene 2003, 22:7359–7368. An excellent review of this complicated topic.

    Article  PubMed  CAS  Google Scholar 

  8. Uchida J, Hamaguchi Y, Oliver JA, et al.: The innate mononuclear phagocyte network depletes B lymphocytes through Fc receptor-dependent mechanisms during anti-CD20 antibody immunotherapy. J Exp Med 2004, 199:1659–1669.

    Article  PubMed  CAS  Google Scholar 

  9. Cartron G, Dacheux L, Salles G, et al.: Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood 2002, 99:754–758.

    Article  PubMed  CAS  Google Scholar 

  10. Ghielmini M, Rufibach K, Salles G, et al.: Single agent rituximab in patients with follicular or mantle cell lymphoma: clinical and biological factors that are predictive of response and event-free survival as well as the effect of rituximab on the immune system: a study of the Swiss Group for Clinical Cancer Research (SAKK). Ann Oncol 2005, 16:1675–1682. This article summarizes key prognostic factors in a large group of patients treated with single-agent rituximab.

    Article  PubMed  CAS  Google Scholar 

  11. Weng WK, Levy R: Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J Clin Oncol 2003, 21:3940–3947.

    Article  PubMed  CAS  Google Scholar 

  12. Fisher RI, Dana BW, LeBlanc M, et al.: Interferon alpha consolidation after intensive chemotherapy does not prolong the progression-free survival of patients with low-grade non-Hodgkin's lymphoma: results of the Southwest Oncology Group randomized phase III study 8809. J Clin Oncol 2000, 18:2010–2016.

    PubMed  CAS  Google Scholar 

  13. Cheson BD: The curious case of the baffling biological. J Clin Oncol 2000, 18:2007–2009.

    PubMed  CAS  Google Scholar 

  14. Davis TA, Maloney DG, Grillo-Lopez AJ, et al.: Combination immunotherapy of relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma with rituximab and interferon-alpha-2a. Clin Cancer Res 2000, 6:2644–2652. One of the first published clinical experiences combining rituximab with an immunomodulatory agent.

    PubMed  CAS  Google Scholar 

  15. Sacchi S, Federico M, Vitolo U, et al.: Clinical activity and safety of combination immunotherapy with IFN-alpha 2a and rituximab in patients with relapsed low grade non-Hodgkin's lymphoma. Haematologica 2001, 86:951–958.

    PubMed  CAS  Google Scholar 

  16. Malik UR, Makower DF, Wadler S: Interferon-mediated fatigue. Cancer 2001, 92(Suppl):1664–1668.

    Article  PubMed  CAS  Google Scholar 

  17. Friedberg JW, Neuberg D, Gribben JG, et al.: Combination immunotherapy with rituximab and interleukin-2 in patients with relapsed or refractory follicular non-Hodgkin's lymphoma. Br J Haematol 2002, 117:1–7.

    Article  Google Scholar 

  18. Gluck WL, Hurst D, Yuen A, et al.: Phase I studies of interleukin (IL)-2 and rituximab in B-cell non-Hodgkin's lymphoma: IL-2 mediated natural killer cell expansion correlations with clinical response. Clin Cancer Res 2004, 10:2253–2264.

    Article  PubMed  CAS  Google Scholar 

  19. Ansell SM, Witzig TE, Kurtin PJ, et al.: Phase 1 study of interleukin-12 in combination with rituximab in patients with B-cell non-Hodgkin lymphoma. Blood 2002, 99:67–74.

    Article  PubMed  CAS  Google Scholar 

  20. Liu NS, Grimm EA, Poindexter NJ, et al.: Rituximab, alone and in combination, for treatment of patients with indolent B cell lymphoma. Am J Oncol Rev 2005, 4(Suppl 10):27–33.

    Google Scholar 

  21. Kimby E: Beyond immunochemotherapy: combinations of rituximab with cytokines interferon-alpha2a and granulocyte-macrophage colony stimulating factor. Semin Oncol 2002, 29(Suppl 6):7–10.

    Article  PubMed  CAS  Google Scholar 

  22. van der Kolk LE, Grillo-Lopez AJ, Baars JW, van Oers MH: Treatment of relapsed B-cell non-Hodgkin's lymphoma with a combination of chimeric anti-CD20 monoclonal antibodies (rituximab) and G-CSF: final report on safety and efficacy. Leukemia 2003, 17:1658–1664.

    Article  CAS  Google Scholar 

  23. Reff ME, Carner K, Chambers KS, et al.: Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 1994, 83:435–445.

    PubMed  CAS  Google Scholar 

  24. Golay J, Zaffaroni L, Vaccari T, et al.: Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis. Blood 2000, 95:3900–3908.

    PubMed  CAS  Google Scholar 

  25. van der Kolk LE, Grillo-Lopez AJ, Baars JW, et al.: Complement activation plays a key role in the sideeffects of rituximab treatment. Br J Haematol 2001, 115:807–811.

    Article  PubMed  Google Scholar 

  26. van der Kolk LE, Evers LM, Omene C, et al.: CD20-induced B cell death can bypass mitochondria and caspase activation. Leukemia 2002, 16:1735–1744.

    Article  PubMed  CAS  Google Scholar 

  27. Jazirehi AR, Bonavida B: Cellular and molecular signal transduction pathways modulated by rituximab (rituxan, anti-CD20 mAb) in non-Hodgkin's lymphoma: implications in chemosensitization and therapeutic intervention. Oncogene 2005, 24:2121–2143.

    Article  PubMed  CAS  Google Scholar 

  28. Coleman M, Goldenberg DM, Siegel AB, et al.: Epratuzumab: targeting B-cell malignancies through CD22. Clin Cancer Res 2003, 9:3991S-3994S.

    PubMed  CAS  Google Scholar 

  29. Friedberg JW: Developing new monoclonal antibodies for aggressive lymphoma: a challenging road in the rituximab era. Clin Cancer Res 2004, 10:5297–5298.

    Article  PubMed  Google Scholar 

  30. Leonard J, Coleman M, Matthews J, et al.: High complete response rate following epratuzumab (anti-CD22) and rituximab (anti-CD20) combination antibody therapy in follicular non-Hodgkin's lymphoma. Ann Oncol 2002, 13(Suppl 2):38.

    Google Scholar 

  31. Emmanouilides C, Leonard JP, Schuster SJ, et al.: Multicenter, phase 2 study of combination antibody therapy with epratuzumab plus rituximab in recurring lowgrade NHL. Blood 2003, 102:69a.

    Article  CAS  Google Scholar 

  32. Friedberg JW, Leonard JP, Younes A, et al.: Updated results from a phase II study of galiximab (anti-CD80) in combination with rituximab for relapsed or refractory follicular NHL. Blood 2005, 106:685a.

    Google Scholar 

  33. Klinman DM: Immunotherapeutic uses of CpG oligodeoxynucleotides. Nat Rev Immunol 2004, 4:249–258.

    Article  PubMed  CAS  Google Scholar 

  34. Kawarada Y, Ganss R, Garbi N, et al.: NK- and CD8(+) T cell-mediated eradication of established tumors by peritumoral injection of CpG-containing oligodeoxynucleotides. J Immunol 2001, 167:5247–5253.

    PubMed  CAS  Google Scholar 

  35. Weiner GJ, Liu HM, Wooldridge JE, et al.: Immunostimulatory oligodeoxynucleotides containing the CpG motif are effective as immune adjuvants in tumor antigen immunization. Proc Natl Acad Sci U S A 1997, 94:10833–10837.

    Article  PubMed  CAS  Google Scholar 

  36. Vicari AP, Chiodoni C, Vaure C, et al.: Reversal of tumorinduced dendritic cell paralysis by CpG immunostimulatory oligonucleotide and anti-interleukin 10 receptor antibody. J Exp Med 2002, 196:541–549.

    Article  PubMed  CAS  Google Scholar 

  37. Jahrsdorfer B, Hartmann G, Racila E, et al.: CpG DNA increases primary malignant B cell expression of costimulatory molecules and target antigens. J Leukoc Biol 2001, 69:81–88.

    PubMed  CAS  Google Scholar 

  38. Friedberg JW, Kim H, McCauley M, et al.: Combination immunotherapy with a CpG oligonucleotide (1018 ISS) and rituximab in patients with non-Hodgkin lymphoma: increased interferon-alpha/beta-inducible gene expression, without significant toxicity. Blood 2005, 105:489–495.

    Article  PubMed  CAS  Google Scholar 

  39. Friedberg JW, Kelly J, Kutock JL, et al.: CpG oligonucleotide (1018 ISS) may overcome rituximab resistance in follicular lymphoma through enhanced ADCC, T cell expansion, and alteration of tumor microenvironment. Blood 2005, 106:684a.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. James P. Wilmot Cancer Center, University of Rochester, 601 Elmwood Avenue, Box 704, Room 1-4118C, 14642, Rochester, NY, USA

    Jonathan W. Friedberg MD

Authors
  1. Jonathan W. Friedberg MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Arnold S. Freedman MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Friedberg, J.W., Freedman, A.S. Antibody and immunomodulatory agents in treatment of indolent non-Hodgkin's lymphoma. Curr. Treat. Options in Oncol. 7, 276–284 (2006). https://doi.org/10.1007/s11864-006-0037-2

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11864-006-0037-2

Keywords

Search

Navigation